Canada''s Drug Price Watchdog Rethinks Pricing Guidelines to Improve Affordability of, Access to, Prescription Drugs
Patented Medicine Prices Review Board launches first phase of major consultations to modernize its legal framework
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 06/24/16 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) today launched the first phase of a major consultation initiative that will ultimately change the way the federal government determines whether Canadian patented drug prices are excessive. The PMPRB''s regulatory framework will be modernized and simplified to better protect Canadian consumers from excessive patented drug prices in today''s rapidly evolving pharmaceutical market.
Through the , the PMPRB is seeking to generate an open, informed dialogue with stakeholders and members of the public on areas of the PMPRB''s drug pricing guidelines in need of reform as a result of changes to the pharmaceutical environment in Canada and abroad. Feedback in response to the Guidelines Modernization Discussion Paper and the series of questions it puts forward will shape later phases of the consultation process.
Rethinking the guidelines is an important step toward ensuring the long-term sustainability of the Canadian pharmaceutical system while continuing to improve the accessibility and affordability of prescription drugs.
Comments must be submitted to the PMPRB in writing by October 24, 2016. All comments will be considered public and will be published on the PMPRB website. Written comments may be submitted by e-mail, letter mail or fax to:
Quick Facts
Quotes
"This consultation initiative is aligned with the ongoing efforts of the federal, provincial, and territorial Ministers of Health to lower pharmaceutical prices while enhancing the affordability, accessibility, and appropriate use of prescription drugs."
Mary Catherine Lindberg
Chairperson, Patented Medicine Prices Review Board
"Canada, like many countries, is facing escalating health care costs. These consultations are a necessary first step to modernizing and simplifying the Patented Medicine Prices Review Board''s regulatory framework in order to better protect Canadians from high patented drug prices."
Douglas Clark
Executive Director, Patented Medicine Prices Review Board
Related Products
Additional Links
Follow us on Twitter:
Contacts:
Sofie McCoy-Astell, Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
TTY (telecommunications device for the hearing impaired) -
613-957-4373
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.06.2016 - 08:30 Uhr
Sprache: Deutsch
News-ID 1443546
Anzahl Zeichen: 3268
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
National
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 435 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Canada''s Drug Price Watchdog Rethinks Pricing Guidelines to Improve Affordability of, Access to, Prescription Drugs
"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
